Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 4/20 | 0.39 |
| ▸ | TACR3 | P29371 | 4/20 | 0.39 |
| ▸ | TACR2 | P21452 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402325 | 1.00 | CYP2C9 (0.41) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5411714 | 0.87 | TACR3 (0.49) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5411691 | 0.87 | TACR3 (0.49) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5930898 | 0.81 | MEN1 (0.41) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5392719 | 0.80 | TACR3 (0.47) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5930680 | 0.79 | TACR3 (0.41) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5422711 | 0.79 | KDM4E (0.39) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5422701 | 0.79 | KDM4E (0.39) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5423422 | 0.79 | KDM4E (0.39) | CYP2C9MEN1KMT2AKDM4EMAPT | |
| SCHEMBL5930790 | 0.79 | ALDH1A1 (0.40) | CYP2C9MEN1KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007521276-A | — | — | 2007-08-02 | — | — | JP | claimed |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | claimed |
| EP-1635834-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005000247-A2 | 4-CARBOXAMIDO QUINOLINE DERIVATIVES FOR USE AS NK-2 AND NK-3 | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | claimed |
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | SMITHKLINE BEECHAM CORPORATION | 2007-03-15 | — | — | US | disclosed |
| EP-1635834-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005000247-A2 | 4-CARBOXAMIDO QUINOLINE DERIVATIVES FOR USE AS NK-2 AND NK-3 | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060593-A1 | 4-Carboxamido quinoline derivatives for use as nk-2 and nk-3 | KCNK3, KCNQ3, KCNK2 | CYP2C9 2127/4885MEN1 2344/4885KMT2A 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.